Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026

Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support A…

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and ...

Beam sets hopes on accelerated approval of AATD gene therapy

Beam Therapeutics has set its sights on an accelerated approval of its base editing therapy for the severe form of alpha-1 ...

Beam posts positive data on base editing treatment for AATD

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...

Beam to advance gene-editing drug to pivotal development

Beam Therapeutics (BEAM) stock jumps as the company seeks to move gene-editing drug BEAM-302 to pivotal study in.alpha-1 ...
FierceBiotech

Beam hits hemoglobin goal in first base editing clinical data, reports death tied to conditioning drug

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...